State Street’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-2,994,000
Closed -$141M 4372
2025
Q2
$141M Buy
2,994,000
+77,659
+3% +$3.45M 0.01% 1124
2025
Q1
$129M Sell
2,916,341
-84,645
-3% -$3.9M 0.01% 1141
2024
Q4
$108M Sell
3,000,986
-89,566
-3% -$3.13M ﹤0.01% 1294
2024
Q3
$99M Buy
3,090,552
+3,707
+0.1% +$139K ﹤0.01% 1328
2024
Q2
$116M Buy
3,086,845
+125,221
+4% +$5.27M 0.01% 1170
2024
Q1
$146M Buy
2,961,624
+341,974
+13% +$15.8M 0.01% 1068
2023
Q4
$95.6M Buy
2,619,650
+48,454
+2% +$1.26M ﹤0.01% 1316
2023
Q3
$59.4M Sell
2,571,196
-584,355
-19% -$16M ﹤0.01% 1519
2023
Q2
$82.7M Buy
3,155,551
+344,280
+12% +$9.05M ﹤0.01% 1348
2023
Q1
$72.4M Sell
2,811,271
-944,418
-25% -$27.6M ﹤0.01% 1402
2022
Q4
$97.7M Buy
3,755,689
+431,627
+13% +$10.6M 0.01% 1175
2022
Q3
$94.8M Sell
3,324,062
-565,187
-15% -$16.2M 0.01% 1135
2022
Q2
$95.8M Buy
3,889,249
+2,293,359
+144% +$83.9M 0.01% 1181
2022
Q1
$90.1M Buy
1,595,890
+276,779
+21% +$15.8M ﹤0.01% 1368
2021
Q4
$81.8M Sell
1,319,111
-10,307
-0.8% -$682K ﹤0.01% 1453
2021
Q3
$84.3M Buy
1,329,418
+247,497
+23% +$19.1M ﹤0.01% 1415
2021
Q2
$89.2M Buy
1,081,921
+2,353
+0.2% +$179K ﹤0.01% 1388
2021
Q1
$79.4M Buy
1,079,568
+1,616
+0.1% +$127K ﹤0.01% 1408
2020
Q4
$78.2M Buy
1,077,952
+281,110
+35% +$18.1M ﹤0.01% 1343
2020
Q3
$38M Buy
796,842
+421,306
+112% +$17.9M ﹤0.01% 1646
2020
Q2
$15.8M Buy
375,536
+202,117
+117% +$7.19M ﹤0.01% 2158
2020
Q1
$4.68M Buy
173,419
+28,166
+19% +$918K ﹤0.01% 2659
2019
Q4
$5.59M Buy
+145,253
New +$3.4M ﹤0.01% 2798

Other funds holding SWTX

State Street's SWTX Position: Q3 2025 in Review

State Street sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 2,994,000 shares — an estimated $141M sold.

State Street first reported a position in SWTX in Q4 2019 and held it in 23 quarters. The position peaked at $146M in Q1 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • State Street reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • State Street sold 2,994,000 SpringWorks Therapeutics shares in Q3 2025, an estimated $141M.
  • State Street first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 23 quarters.
  • State Street's SpringWorks Therapeutics position peaked at $146M in Q1 2024.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.